Royal Free Hospital

Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach (2019) Peyrin-Biroulet L, Danese S, Cummings F, Atreya R, Greveson K, Pieper B, Kang T Journal article, Review article Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort (2019) Wu W, Jordan S, Graf N, Pena JDO, Curram J, Allanore Y, Matucci-Cerinic M, et al. Journal article Long-Term Follow Up of Patients With Carcinoid Syndrome Diarrhea Treated With Telotristat Ethyl: A Pooled Analysis of Phase 2 and 3 Trials (2019) Anthony L, Kulke M, Caplin M, Bergsland E, Oberg K, Pavel ME, Horsch D, et al. Conference contribution Outcomes and Risk Score for Distal Pancreatectomy with Celiac Axis Resection (DP-CAR): An International Multicenter Analysis (2019) Klompmaker S, Peters NA, Van Hilst J, Bassi C, Boggi U, Busch OR, Niesen W, et al. Journal article Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors (2019) Dromain C, Pavel ME, Ruszniewski P, Langley A, Massien C, Baudin E, Caplin ME Journal article EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†. (2019) Horwich A, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, et al. Journal article Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome. (2019) Anthony LB, Kulke MH, Caplin ME, Bergsland E, Oberg K, Pavel M, Hoersch D, et al. Journal article Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology (2019) Butler EA, Baron M, Fogo AB, Frech T, Ghossein C, Hachulla E, Hoa S, et al. Journal article Unmet medical needs in metastatic lung and digestive neuroendocrine neoplasms (2019) Capdevila J, Bodei L, Davies P, Gorbounova V, Jensen RT, Knigge UP, Krejs GJ, et al. Journal article Treatment efficacyand safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12-and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study (2018) Hirschfield G, Boudes P, Bowlus C, Gitlin N, Michael G, Harrison S, Gordon SC, et al. Conference contribution